Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142793 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KDM4EL3MBTL1POLBMEN1 | |
| SCHEMBL30703390 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KDM4EL3MBTL1POLBMEN1 | |
| SCHEMBL16838776 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KDM4EL3MBTL1POLBMEN1 | |
| SCHEMBL31621360 | 0.83 | ALDH1A1 (0.81) | ALDH1A1KDM4EL3MBTL1POLBMEN1 | |
| 6-Chloronicotinaldehyde SCHEMBL453853 | 0.81 | — | — | |
| 6-Chloronicotinaldehyde SCHEMBL29694763 | 0.81 | — | — | |
| SCHEMBL8006810 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4EL3MBTL1POLBMEN1 | |
| 6-Chloronicotinaldehyde SCHEMBL27615551 | 0.79 | ALDH1A1 (0.49) | ALDH1A1KDM4EL3MBTL1MEN1MAPT | |
| SCHEMBL4597870 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4EL3MBTL1POLBNPC1 | |
| SCHEMBL24400539 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4EL3MBTL1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | ALDH1A1 3484/4885KDM4E 3689/4885L3MBTL1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.